CZ286202B6 - Farmaceutický přípravek - Google Patents

Farmaceutický přípravek Download PDF

Info

Publication number
CZ286202B6
CZ286202B6 CZ19941825A CZ182594A CZ286202B6 CZ 286202 B6 CZ286202 B6 CZ 286202B6 CZ 19941825 A CZ19941825 A CZ 19941825A CZ 182594 A CZ182594 A CZ 182594A CZ 286202 B6 CZ286202 B6 CZ 286202B6
Authority
CZ
Czechia
Prior art keywords
lipase
acarbose
alpha
inhibition properties
tetrahydrolipstatin
Prior art date
Application number
CZ19941825A
Other languages
Czech (cs)
English (en)
Other versions
CZ182594A3 (en
Inventor
Klaus-Dieter Bremer
Pavel Sawlewicz
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CZ182594A3 publication Critical patent/CZ182594A3/cs
Publication of CZ286202B6 publication Critical patent/CZ286202B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
CZ19941825A 1993-08-05 1994-07-29 Farmaceutický přípravek CZ286202B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH233993 1993-08-05

Publications (2)

Publication Number Publication Date
CZ182594A3 CZ182594A3 (en) 1995-02-15
CZ286202B6 true CZ286202B6 (cs) 2000-02-16

Family

ID=4231504

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ19941825A CZ286202B6 (cs) 1993-08-05 1994-07-29 Farmaceutický přípravek

Country Status (24)

Country Link
US (1) US5643874A (es)
EP (1) EP0638317B1 (es)
JP (1) JP2780932B2 (es)
KR (1) KR100342285B1 (es)
CN (1) CN1076196C (es)
AT (1) ATE190503T1 (es)
AU (1) AU684793B2 (es)
BR (1) BR9403170A (es)
CA (1) CA2128044C (es)
CZ (1) CZ286202B6 (es)
DE (1) DE59409200D1 (es)
DK (1) DK0638317T3 (es)
ES (1) ES2144019T3 (es)
GR (1) GR3033643T3 (es)
HU (1) HU222346B1 (es)
IL (1) IL110510A (es)
NO (1) NO313490B1 (es)
NZ (1) NZ264142A (es)
PL (1) PL175997B1 (es)
PT (1) PT638317E (es)
RU (1) RU2141844C1 (es)
SA (1) SA94150156B1 (es)
TW (1) TW381025B (es)
ZA (1) ZA945673B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298468B6 (cs) * 1997-06-23 2007-10-10 N-Gene Research Laboratories Inc. Farmaceutické prostredky se zesílenou protinádorovou aktivitou a/nebo sníženými nežádoucími úcinky obsahující protinádorové cinidlo a derivát kyseliny hydroximové

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1017408B1 (en) * 1997-02-05 2005-04-13 F. Hoffmann-La Roche Ag Use of tethrahydrolipstatin in the treatment of diabetes type ii
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6267952B1 (en) * 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
DE19802700A1 (de) * 1998-01-24 1999-07-29 Bayer Ag Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält
PT1105122E (pt) * 1998-08-14 2005-08-31 Hoffmann La Roche Composicoes farmaceuticas que contem inibidores de lipase
NZ510311A (en) * 1998-09-08 2003-08-29 Smithkline Beecham Corp Lipstatin derivative - soluble fiber tablets
JP2002535288A (ja) 1999-01-22 2002-10-22 ウンツァ ディ マリア カルメラ マラッツィータ エッセ．ア．エッセ． リポタンパク質複合体およびそれらを含む組成物
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US6235305B1 (en) * 1999-10-29 2001-05-22 2Pro Chemical Essentially nonabsorbable lipase inhibitor derivatives, pharmaceutical compositions and methods of use therefor
US6348492B1 (en) * 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
WO2001032670A1 (en) * 1999-10-29 2001-05-10 John Jason Gentry Mullins Oxetanone derivatives
US6342519B2 (en) * 1999-10-29 2002-01-29 2 Pro Chemical Oxetanone derivatives
KR100349334B1 (ko) * 1999-12-08 2002-08-21 박관화 아카비오신 글루코실 시몬진 및 그것의 제조방법.
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
AU8969901A (en) * 2000-07-28 2002-02-13 Hoffmann La Roche New pharmaceutical composition
ATE293477T1 (de) * 2000-07-28 2005-05-15 Hoffmann La Roche Neue verwendung von lipase-inhibitoren
US6849609B2 (en) * 2001-04-10 2005-02-01 James U. Morrison Method and composition for controlled release acarbose formulations
US6734314B2 (en) 2001-12-04 2004-05-11 Biogal Gyogyszergyar Rt. Preparation of orlistat and orlistat crystalline forms
US7108869B2 (en) * 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US20060185357A1 (en) * 2004-05-07 2006-08-24 Kovacevich Ian D Independently drawing and tensioning lines with bi-directional rotary device having two spools
EP3263118B1 (en) 2004-05-10 2019-09-25 University of Copenhagen Flaxseeds for body weight management
US20060029567A1 (en) * 2004-08-04 2006-02-09 Bki Holding Corporation Material for odor control
KR20070084455A (ko) * 2004-11-23 2007-08-24 워너-램버트 캄파니 엘엘씨 지질혈증 치료용 ｈｍｇ ｃｏ-ａ 환원효소 억제제로서의7-(2ｈ-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
US20070009615A1 (en) * 2005-04-29 2007-01-11 Litao Zhong Compositions and methods for controlling glucose uptake
PT1897558E (pt) * 2005-06-09 2013-11-06 Norgine Bv Preparação sólida de 2-hexadeciloxi-6-metil-4h-3,1- benzoxazin-4-ona
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
CN100349614C (zh) * 2005-10-21 2007-11-21 南京工业大学 一种含α－淀粉酶抑制剂的固体混合物及其制备工艺和在制药中的应用
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8138188B2 (en) * 2006-02-23 2012-03-20 Pfizer Inc. Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
TW200831497A (en) * 2006-10-12 2008-08-01 Epix Delaware Inc Carboxamide compounds and their use
CA2669311C (en) 2006-11-13 2011-09-20 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
JP2010510201A (ja) * 2006-11-20 2010-04-02 グレンマーク・ファーマシューティカルズ・エスエー ステアリン酸ＣｏＡ脱飽和酵素阻害剤としてのアセチレン誘導体
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
SI2002825T1 (sl) * 2007-06-14 2013-10-30 Krka Farmacevtski sestavki, ki obsegajo orlistat
EP2625968A1 (en) 2007-09-12 2013-08-14 Københavns Universitet Composition and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
JP2011506466A (ja) 2007-12-11 2011-03-03 株式会社サイトパスファインダー カルボキサミド化合物ならびにケモカイン受容体アゴニストとしてのそれらの使用
CA2731897C (en) * 2008-08-06 2013-07-02 Pfizer Limited Diazepine and diazocane compounds as mc4 agonists
JP5752359B2 (ja) * 2010-02-25 2015-07-22 富士フイルム株式会社 体重増加抑制組成物及びこれを含む食品
JP2013528172A (ja) 2010-05-21 2013-07-08 ファイザー・インク ２−フェニルベンゾイルアミド
TR201100148A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Stabil akarboz förmülasyonları.
WO2012120414A2 (en) 2011-03-04 2012-09-13 Pfizer Inc. Edn3-like peptides and uses thereof
CN102805744A (zh) * 2011-06-02 2012-12-05 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
CN102872062A (zh) * 2011-07-13 2013-01-16 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
US8252312B1 (en) * 2011-12-27 2012-08-28 David Wong Oral solid composition comprising a lipid absorption inhibitor
US20150050371A1 (en) 2012-03-09 2015-02-19 Biotropics Malaysia Berhad Extract Formulations of Rhodamnia Cinerea And Uses Thereof
CN104812737A (zh) * 2012-05-08 2015-07-29 塞利克斯比奥私人有限公司 用于治疗高血糖症的组合物和方法
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
FR3017536B1 (fr) 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
MY195038A (en) * 2014-12-17 2023-01-04 Empros Pharma Ab A Modified Release Composition of Orlistat and Acarbose for the Treatment of Obesity and Related Metabolic Disorders
KR101903150B1 (ko) 2016-09-12 2018-10-01 가톨릭대학교산학협력단 퀴니자린을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
CN107308154A (zh) * 2017-07-19 2017-11-03 重庆植恩药业有限公司 治疗或预防肥胖症以及代谢综合征的药物组合物及其应用
EP3911648A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
JPS5953920B2 (ja) * 1977-12-28 1984-12-27 東洋醸造株式会社 新規なアミノ糖化合物およびその製法
CA1121290A (en) * 1978-02-14 1982-04-06 Yasuji Suhara Amino sugar derivatives
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
FI844289L (fi) * 1984-01-21 1985-07-22 Hoechst Ag Nya polypeptider med -amylashaemmande verkan, foerfarande foer deras framstaellning, deras anvaendning och farmaceutiska preparat.
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
EP0364696B1 (en) * 1988-08-22 1993-03-17 Takeda Chemical Industries, Ltd. Alpha-glucosidase inhibitor as a calcium absorption promotor
DK244090D0 (da) * 1990-10-09 1990-10-09 Novo Nordisk As Kemiske forbindelser
US5240962A (en) * 1991-04-15 1993-08-31 Takasago Institute For Interdisciplinary Science, Inc. Antiobesity and fat-reducing agents
GB9122051D0 (en) * 1991-10-17 1991-11-27 Univ Nottingham Medicines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298468B6 (cs) * 1997-06-23 2007-10-10 N-Gene Research Laboratories Inc. Farmaceutické prostredky se zesílenou protinádorovou aktivitou a/nebo sníženými nežádoucími úcinky obsahující protinádorové cinidlo a derivát kyseliny hydroximové

Also Published As

Publication number Publication date
ZA945673B (en) 1995-02-07
NO313490B1 (no) 2002-10-14
AU684793B2 (en) 1998-01-08
CN1106701A (zh) 1995-08-16
ES2144019T3 (es) 2000-06-01
SA94150156B1 (ar) 2005-05-15
RU94028653A (ru) 1996-09-10
IL110510A (en) 1999-03-12
CZ182594A3 (en) 1995-02-15
CN1076196C (zh) 2001-12-19
AU6883994A (en) 1995-02-16
EP0638317B1 (de) 2000-03-15
ATE190503T1 (de) 2000-04-15
NO942900L (no) 1995-02-06
PT638317E (pt) 2000-07-31
HU9402249D0 (en) 1994-09-28
HUT68300A (en) 1995-06-28
DE59409200D1 (de) 2000-04-20
DK0638317T3 (da) 2000-06-26
JP2780932B2 (ja) 1998-07-30
NZ264142A (en) 1996-11-26
HU222346B1 (hu) 2003-06-28
KR100342285B1 (ko) 2002-10-25
PL304557A1 (en) 1995-02-06
US5643874A (en) 1997-07-01
GR3033643T3 (en) 2000-10-31
PL175997B1 (pl) 1999-03-31
RU2141844C1 (ru) 1999-11-27
CA2128044A1 (en) 1995-02-06
TW381025B (en) 2000-02-01
CA2128044C (en) 2007-02-20
JPH0753409A (ja) 1995-02-28
IL110510A0 (en) 1994-11-11
BR9403170A (pt) 1995-04-18
KR950005319A (ko) 1995-03-20
NO942900D0 (es) 1994-08-04
EP0638317A1 (de) 1995-02-15

Similar Documents

Publication Publication Date Title
CZ286202B6 (cs) Farmaceutický přípravek
Pearson et al. Niclosamide therapy for tapeworm infections
KR960016582B1 (ko) 위장장해의 치료 및 예방용 약제학적 조성물
KR100257367B1 (ko) 위장관 질환 치료용 약제
CA2382887A1 (en) Immunopotentiating compositions
CN1279582A (zh) 用于口服的含血清素配方及其使用方法
US3764672A (en) Composition and process of treatment using lincomycin derivatives
JP3455633B2 (ja) 潰瘍性大腸炎の予防又は治療剤
US20050137265A1 (en) Rapidly dissolving metoclopramide solid oral dosage and method thereof
Ashida et al. Clinical study on the pathophysiology and treatment of PPI-resistant ulcers
US3996356A (en) Composition containing 5-sulfanilamido-3,4-dimethylisoxazole and a trimethoxybenzyl pyrimidine
Redding et al. A comparison between fluconazole tablets and clotrimazole troches for the treatment of thrush in HIV infection
HU222835B1 (hu) Amino-purin antivírusos szerek alkalmazása latens herpeszvírus-fertőzés kezelésére és megelőzésére szolgáló gyógyszerkészítmények hatóanyagaként
AHONEN et al. Ketoconazole is Effective against the Chronic Mucocutaneous Candidosis of Autoimmune Polyendocrinopathy‐Candidosis‐Ectodermal Dystrophy (APECED)
US20040192781A1 (en) Method of administration for metoclopramide and pharmaceutical formulation therefor
EP1075257A1 (en) Use of triclosan for the treatment of helicobacter pylori infections
JPH0327313A (ja) 生理的用量のビタミンａと治療活性のある各種有効成分とを有する組成物
KR102251360B1 (ko) 오로볼을 함유하는 설사 개선용 식품 조성물 및 예방 또는 치료용 약학 조성물
CN114796252A (zh) 一类罗红霉素和西米替丁的复方制剂及制备方法
JP2002265354A (ja) 抗ピロリ菌剤組成物
PT100729A (pt) Processo para a preparacao de um medicamento contendo subsalicilato de bismuto para tratamento antimicrobiano
RU2161497C2 (ru) Способ лечения дисбактериозов кишечника у детей и взрослых
CN114558009A (zh) 一种由阿莫西林和西咪替丁制备的复方制剂及制备方法
AU2002312652B2 (en) Laxative preparation
SU1252333A1 (ru) Способ лечени дисбактериозов кишечника

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MK4A Patent expired

Effective date: 20140729